ANI Pharmaceuticals Inc
NASDAQ:ANIP

Watchlist Manager
ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Watchlist
Price: 54.16 USD -0.4%
Market Cap: 1.1B USD
Have any thoughts about
ANI Pharmaceuticals Inc?
Write Note

ANI Pharmaceuticals Inc
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ANI Pharmaceuticals Inc
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Total Other Income
-$2.7m
CAGR 3-Years
-13%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Total Other Income
-$195m
CAGR 3-Years
N/A
CAGR 5-Years
33%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Total Other Income
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Total Other Income
$1.1B
CAGR 3-Years
42%
CAGR 5-Years
205%
CAGR 10-Years
-1%
Eli Lilly and Co
NYSE:LLY
Total Other Income
$439.4m
CAGR 3-Years
-18%
CAGR 5-Years
8%
CAGR 10-Years
7%
No Stocks Found

ANI Pharmaceuticals Inc
Glance View

Market Cap
1.1B USD
Industry
Pharmaceuticals

ANI Pharmaceuticals Inc. operates at the heart of the pharmaceutical industry with a focused strategy that blends generics with niche high-value medications. Born in the realm of specialty pharmaceuticals, the company has crafted a business model that leverages both organic growth and strategic acquisitions. This dual approach helps the company to broaden its product offerings and maintain a robust pipeline. By targeting niche markets often overlooked by larger pharmaceutical giants, ANI maximizes its opportunities in areas with less competitive congestion. Central to its operations is the manufacturing and marketing of generic prescription products that are not only critically required but also pose less risk of commoditization due to their complexity, regulatory hurdles, or limited manufacturing capabilities. Revenue generation for ANI is a sophisticated blend of manufacturing, marketing, and brand positioning. The company's infrastructure supports integrated product development, regulatory approval, and scalable manufacturing processes. This allows them to efficiently bring to market a diverse portfolio of more than a hundred products across therapeutic areas. Additionally, ANI taps into revenue streams by producing legacy branded drugs often acquired from larger players looking to offload non-core assets. These legacy products, while sometimes in smaller volumes, benefit from loyal prescriber bases and established market presence, providing a steady income for the company. In essence, ANI Pharmaceuticals thrives on navigating the intricacies of the pharmaceutical supply chain, seizing opportunities in underexplored niches and refocusing the potential of undervalued brands.

ANIP Intrinsic Value
93.06 USD
Undervaluation 42%
Intrinsic Value
Price

See Also

What is ANI Pharmaceuticals Inc's Total Other Income?
Total Other Income
-2.7m USD

Based on the financial report for Sep 30, 2024, ANI Pharmaceuticals Inc's Total Other Income amounts to -2.7m USD.

What is ANI Pharmaceuticals Inc's Total Other Income growth rate?
Total Other Income CAGR 5Y
-35%

Over the last year, the Total Other Income growth was -2 620%. The average annual Total Other Income growth rates for ANI Pharmaceuticals Inc have been -13% over the past three years , -35% over the past five years .

Back to Top